How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned?

E. Sila Ozdemir; Srivathsan V. Ranganathan; Ruth Nussinov

doi:10.1080/17460441.2022.2128333

How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned?

E. Sila Ozdemir, Srivathsan V. Ranganathan, Ruth Nussinov^*

^*Corresponding author for this work

Human Molecular Genetics Biochemistry

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1061-1065
Number of pages	5
Journal	Expert Opinion on Drug Discovery
Volume	17
Issue number	10
DOIs	https://doi.org/10.1080/17460441.2022.2128333
State	Published - 2022

Keywords

COVID-19
Drug repurposing
artificial intelligence
computational biology
knowledge graph
machine learning
personalized treatment
precision medicine

Access to Document

10.1080/17460441.2022.2128333

Cite this

@article{58d89b5c496d42e3b8087caee894d1a5,

title = "How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned?",

keywords = "COVID-19, Drug repurposing, artificial intelligence, computational biology, knowledge graph, machine learning, personalized treatment, precision medicine",

author = "Ozdemir, {E. Sila} and Ranganathan, {Srivathsan V.} and Ruth Nussinov",

note = "Funding Information: This paper was supported by federal funds from the Frederick National Laboratory for Cancer Research, NIH [HHSN261201500003I] to R Nussinov; and by the Intramural Research Program of the NIH, Frederick National Laboratory for Cancer Research, to R Nussinov. ES Ozdemir and SV Ranganathan are members of and supported by the Cancer Early Detection Advanced Research (CEDAR) at Oregon Health & Science University, Knight Cancer Institute Center of the OHSU Knight Cancer Institute.",

year = "2022",

doi = "10.1080/17460441.2022.2128333",

language = "אנגלית",

volume = "17",

pages = "1061--1065",

journal = "Expert Opinion on Drug Discovery",

issn = "1746-0441",